{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:42:13Z","timestamp":1759383733823,"version":"3.41.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the visual and anatomical impact of intravitreal injection treatment deferral because of the COVID-19 lockdown on patients affected by neovascular age-related macular degeneration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively reviewed 314 patients (394 eyes) who were scheduled to receive the impact of intravitreal injections during the Swiss lockdown. We compared patients who continued to receive scheduled impact of intravitreal treatment without clinical consultation (Group Continue \u201fC\u201d; n = 215) and patients for whom the impact of intravitreal treatment was completely deferred (Group Stop, \u201fS\u201d; n = 179). Functional and anatomical parameters were collected at four time points before and after the lockdown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In Group C, the visual acuity at baseline and after the lockdown did not differ significantly. In Group S, the visual acuity deteriorated significantly compared with baseline and then improved slightly after the resumption of treatment, but it did not recover to baseline values. The mean central subfield thickness remained stable in Group C, whereas it increased in Group S and then returned to prelockdown values after the resumption of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>An \u201cinjection-only\u201d approach was effective in managing patients with neovascular age-related macular degeneration during the pandemic lockdown, whereas patients who deferred their scheduled treatment showed partially irreversible deterioration of visual function. We recommend treatment continuation in patients with neovascular age-related macular degeneration during a lockdown.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003369","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T23:00:43Z","timestamp":1639609243000},"page":"634-642","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN"],"prefix":"10.1097","volume":"42","author":[{"given":"Andrea","family":"Montesel","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Fondation Asile des Aveugles, Jules Gonin Eye Hospital, Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Gigon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Fondation Asile des Aveugles, Jules Gonin Eye Hospital, Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarice","family":"Giacuzzo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Fondation Asile des Aveugles, Jules Gonin Eye Hospital, Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmela","family":"Mantel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Fondation Asile des Aveugles, Jules Gonin Eye Hospital, Lausanne, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-1689","authenticated-orcid":false,"given":"Chiara M.","family":"Eandi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Fondation Asile des Aveugles, Jules Gonin Eye Hospital, Lausanne, Switzerland; and"},{"name":"Department of Surgical Sciences, University of Torino, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","article-title":"Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis","volume":"104","author":"Li","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R3-20250607","first-page":"CD005139","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"8","author":"Solomon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/bjophthalmol-2013-304556","article-title":"Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen","volume":"98","author":"Mantel","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/eye.2014.321","article-title":"Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results","volume":"29","author":"Gianniou","year":"2015","journal-title":"Eye (Lond)"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00417-017-3762-2","article-title":"Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept","volume":"255","author":"Parvin","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.4.3.6","article-title":"Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements","volume":"4","author":"Mantel","year":"2015","journal-title":"Transl Vis Sci Technol"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2020.06.028","article-title":"Eliminating visual acuity and dilated fundus examinations improves cost efficiency of performing optical coherence tomogrpahy\u2013guided intravitreal injections","volume":"219","author":"Trivizki","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/jamaophthalmol.2020.2004","article-title":"Ophthalmology after coronavirus disease 2019 (COVID-19): transition back to patient care","volume":"138","author":"Parke","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R16-20250607","first-page":"1","article-title":"Review of clinical and operative recommendations for ophthalmology practices during the COVID-19 pandemic","author":"Hoeferlin","year":"2021","journal-title":"SN Compr Clin Med"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"e000487","DOI":"10.1136\/bmjophth-2020-000487","article-title":"Ophthalmology practice during the COVID-19 pandemic","volume":"5","author":"Safadi","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.oret.2017.09.017","article-title":"Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS","volume":"2","author":"Framme","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","article-title":"Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic","volume":"258","author":"Korobelnik","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/IAE.0000000000002941","article-title":"The impact of coronavirus disease (COVID-19) pandemic on intravitreal injections treatment for macular diseases: report from a referral hospital in Milan","volume":"41","author":"Viola","year":"2021","journal-title":"Retina"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.oret.2020.06.027","article-title":"Increased number of submacular hemorrhages as a consequence of coronavirus disease 2019 lockdown","volume":"4","author":"Romano","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/ICU.0000000000000692","article-title":"Real-world vitreoretinal practice patterns during the 2020 COVID-19 pandemic: a nationwide, aggregated health record analysis","volume":"31","author":"Xu","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.576275","article-title":"Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China","volume":"7","author":"Yang","year":"2020","journal-title":"Front Med"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/OPTH.S296345","article-title":"Short-term effects of COVID-19-related deferral of intravitreal injection visits","volume":"15","author":"Ashkenazy","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor","volume":"4","author":"Soares","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jfo.2021.02.001","article-title":"Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment","volume":"44","author":"Yeter","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/s41433-020-0799-y","article-title":"Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration","volume":"34","author":"Chakravarthy","year":"2020","journal-title":"Eye (Lond)"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00417-012-2090-9","article-title":"Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration","volume":"251","author":"Mantel","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:04:06Z","timestamp":1749319446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003369"}},"subtitle":["Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration"],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003369","relation":{},"ISSN":["0275-004X"],"issn-type":[{"type":"print","value":"0275-004X"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}